Drug General Information (ID: DDI5JKSWZI)
  Drug Name Levothyroxine Drug Info Iodide I-131 Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antithyroid Agents Radiopharmaceuticals
  Structure

 Mechanism of Levothyroxine-Iodide I-131 Interaction (Severity Level: Moderate)
     Interference of cell/tissue uptake Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Levothyroxine Iodide I-131
      Mechanism Interfere with the therapeutic effect and/or diagnostic result of radioiodides Radioiodide
      Key Mechanism Factor 1
Factor Name Pharmacokinetics
Factor Description Alters the distribution of the drug, leading to changes in the plasma concentration of the drug and affecting the pharmacological effects.
      Mechanism Description
  • Interference of cell/tissue uptake of Iodide I-131 by Levothyroxine 

Recommended Action
      Management Liothyronine (triiodothyronine) should be withheld for at least 10 days and levothyroxine (thyroxine) for 6 weeks before administering sodium iodide I-131 or I-123, and for 2 weeks after treatment.

References
1 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
2 Lampe WT "Hypoglycemia due to acetohexamide." Arch Intern Med 120 (1967): 239-41. [PMID: 4952678]
3 Multum Information Services, Inc. Expert Review Panel.